Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

  • receive the eCopy two days prior to the printed edition.
  • can partake in our online MCQs.
  • can enter our online sports quiz.


Medicalindependent.ie is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

You are reading 1 of 2 free-access articles allowed for 30 days

First new drug in over 20 years reduces recurrence in high-risk hormone receptor-positive early breast cancer

By Mindo - 12th Nov 2020 | 36 views

Unrecognizable female gynocologist looking at a patients mammogram at the hospital

Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25 per cent in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study at ESMO 2020. “This is the first time in more than 20 years that we have seen an advance in the adjuvant treatment of this form of breast cancer,” said lead author Prof Stephen Johnston, from the Royal Marsden Hospital NHS Foundation Trust, London, UK. Hormone receptor positive breast cancer remains the commonest form of breast cancer, affecting 70 per cent of patients, with most being diagnosed with early disease. 

“Many of these patients can be cured with currently available treatments: Surgery, radiotherapy, chemotherapy, and hormone treatment. But about 20 per cent have high-risk disease and will develop a recurrence either locally in the breast or elsewhere in the body over the first 10 years of treatment,” he explained.  The international phase 3 monarchE study included 5,637 patients with HR+ HER2- early breast cancer with clinical and/ or pathological risk factors putting them at high-risk for relapse. After completing their primary treatment they were randomised on an open-label basis to abemaciclib (150mg twice daily for two years) plus endocrine therapy or endocrine therapy alone. “We found a 25 per cent reduction in recurrence of cancer with the first two years when abemaciclib was added to hormone therapy compared to hormone therapy alone,” reported Prof Johnston. During this time 11.3 per cent of patients in the control group had a relapse of their cancer compared to 7.8 per cent of those in the abemaciclib group, an absolute difference of 3.5 per cent, which translates to a 25.3 per cent reduction in risk. Most of the reductions occurred in sites of distant metastases, especially to liver and bone.

Leave a Reply

Latest
Latest Issue
medical news
The Medical Independent 19th May 2022

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read